{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:23Z","timestamp":1788931223131,"version":"build-2803163510"},"reference-count":17,"publisher":"Bentham Science Publishers Ltd.","issue":"5","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Immune checkpoint inhibitors (ICIs), as novel antitumor drugs, have been widely used in the clinic and have shown good antitumor effects. However, their wide-spread use has also led to the emergence of various immune-related adverse events (IrAEs). Hypophysitis is a rare but serious IrAE. Due to its complex and changeable clinical manifestations, hypophysitis may be easily overlooked, leading to delayed diagnosis and treatment<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>A 68-year-old male patient was diagnosed with bladder cancer (T2bNXM0) in October 2021. He received two cycles of immunotherapy with sintilimab and chemotherapy with gemcitabine and cisplatin (GC). One month after the second treatment, he gradually developed recurrent fever, anorexia, drowsiness, and delirium. Laboratory examination revealed hyponatremia, decreased adrenocorticotropic hormone, and hypocortisolemia. The pituitary MRI showed no abnormality. The patient was diagnosed with immunotherapy-induced hypophysitis (IH) caused by sintilimab, leading to downstream endocrine disorders. With hormone replacement therapy, he was in a good mood, had a good appetite, and made an overall recovery.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Immunotherapy-induced hypophysitis (IH) can result in a severe adrenal crisis, and prompt recognition and diagnosis are crucial. Clinicians must remain vigilant for the possibility of IH in patients who exhibit recurrent fever, anorexia, cognitive decline, and personality changes following ICI treatment. It is imperative to consider this diagnosis early to initiate appropriate management promptly.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0118715303257557231002064417","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T07:54:40Z","timestamp":1697010880000},"page":"606-610","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer:\nA Case Report"],"prefix":"10.2174","volume":"24","author":[{"given":"Ran","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baichuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"Naimi A.","year":"2022","unstructured":"Naimi A.; Mohammed R.N.; Raji A.; Chupradit S.; Yumashev A.V.; Suksatan W.; Shalaby M.N.; Thangavelu L.; Kamrava S.; Shomali N.; Sohrabi A.D.; Adili A.; Noroozi-Aghideh A.; Razeghian E.; Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal  2022,20(1),44","journal-title":"Cell Commun Signal"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"Johnson D.B.","year":"2022","unstructured":"Johnson D.B.; Nebhan C.A.; Moslehi J.J.; Balko J.M.; Immune-checkpoint inhibitors: Long-term implications of toxicity. Nat Rev Clin Oncol  2022,19(4),254-267","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","volume":"14","author":"Di Dalmazi G.","year":"2019","unstructured":"Di Dalmazi G.; Ippolito S.; Lupi I.; Caturegli P.; Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment. Expert Rev Endocrinol Metab  2019,14(6),381-398","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Mai W.; Jiang W.; Geng Q.; Sintilimab: A promising anti-tumor pd-1 antibody. Front Oncol  2020,10,594558","journal-title":"Front Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"Yi M.","year":"2022","unstructured":"Yi M.; Zheng X.; Niu M.; Zhu S.; Ge H.; Wu K.; Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer  2022,21(1),28","journal-title":"Mol Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"736955","DOI":"10.3389\/fonc.2021.736955","volume":"11","author":"Lou B.","year":"2021","unstructured":"Lou B.; Wei H.; Yang F.; Wang S.; Yang B.; Zheng Y.; Zhu J.; Yan S.; Preclinical characterization of GLS-010 (Zimberelimab), a novel fully human Anti-PD-1 therapeutic monoclonal antibody for cancer. Front Oncol  2021,11,736955","journal-title":"Front Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"Dolladille C.","year":"2020","unstructured":"Dolladille C.; Ederhy S.; Sassier M.; Cautela J.; Thuny F.; Cohen A.A.; Fedrizzi S.; Chr\u00e9tien B.; Da-Silva A.; Plane A.F.; Legallois D.; Milliez P.U.; Lelong-Boulouard V.; Alexandre J.; Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol  2020,6(6),865-871","journal-title":"JAMA Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","volume":"9","author":"Lemiale V.","year":"2019","unstructured":"Lemiale V.; Meert A.P.; Vincent F.; Darmon M.; Bauer P.R.; Van de Louw A.; Azoulay E.; Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Ann Intensive Care  2019,9(1),25","journal-title":"Ann Intensive Care"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/ERC-21-0228","volume":"28","author":"Iglesias P.","year":"2021","unstructured":"Iglesias P.; Peir\u00f3 I.; Biagetti B.; Paja-Fano M.; Cobo D.A.; Garc\u00eda G\u00f3mez C.; Mateu-Salat M.; Genua I.; Majem M.; Riudavets M.; Gavira J.; Lamas C.; Fern\u00e1ndez Pombo A.; Guerrero-P\u00e9rez F.; Villabona C.; Cabezas Agr\u00edcola J.M.; Webb S.M.; D\u00edez J.J.; Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Endocr Relat Cancer  2021,28(12),783-792","journal-title":"Endocr Relat Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.beem.2021.101601","volume":"36","author":"Bando H.","year":"2022","unstructured":"Bando H.; Kanie K.; Takahashi Y.; Paraneoplastic autoimmune hypophysitis: An emerging concept. Best Pract Res Clin Endocrinol Metab  2022,36(3),101601","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) National Cancer Institute"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"de Filette J.","year":"2019","unstructured":"de Filette J.; Andreescu C.; Cools F.; Bravenboer B.; Velkeniers B.; A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res  2019,51(3),145-156","journal-title":"Horm Metab Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"Sznol M.","year":"2017","unstructured":"Sznol M.; Postow M.A.; Davies M.J.; Pavlick A.C.; Plimack E.R.; Shaheen M.; Veloski C.; Robert C.; Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev  2017,58,70-76","journal-title":"Cancer Treat Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1007\/s00432-023-04659-5","volume":"149","author":"Esteves-Ferreira S.","year":"2023","unstructured":"Esteves-Ferreira S.; Rosinha P.; Immune checkpoint inhibitor-induced hypophysitis: Clinical and biochemical features. J Cancer Res Clin Oncol  2023,149(10),7925-7932","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.21873\/anticanres.11814","volume":"37","author":"Ariyasu R.","year":"2017","unstructured":"Ariyasu R.; Horiike A.; Yoshizawa T.; Dotsu Y.; Koyama J.; Saiki M.; Sonoda T.; Nishikawa S.; Kitazono S.; Yanagitani N.; Nishio M.; Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res  2017,37(8),4229-4232","journal-title":"Anticancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/ERC-20-0513","volume":"28","author":"Nguyen H.","year":"2021","unstructured":"Nguyen H.; Shah K.; Waguespack S.G.; Hu M.I.; Habra M.A.; Cabanillas M.E.; Busaidy N.L.; Bassett R.; Zhou S.; Iyer P.C.; Simmons G.; Kaya D.; Pitteloud M.; Subudhi S.K.; Diab A.; Dadu R.; Immune checkpoint inhibitor related hypophysitis: Diagnostic criteria and recovery patterns. Endocr Relat Cancer  2021,28(7),419-431","journal-title":"Endocr Relat Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"Haanen J.","year":"2022","unstructured":"Haanen J.; Obeid M.; Spain L.; Carbonnel F.; Wang Y.; Robert C.; Lyon A.R.; Wick W.; Kostine M.; Peters S.; Jordan K.; Larkin J.; Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol  2022,33(12),1217-1238","journal-title":"Ann Oncol"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715303257557231002064417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221929\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715303257557231002064417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:11:40Z","timestamp":1714576300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221929\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715303257557231002064417","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}